

- B
1
Com
6. (amended) A compound as claimed in claim 1 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
7. (amended) A compound as claimed in claim 1 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
8. (amended) A compound as claimed in claim 1 wherein p is 1 or 2 and each R¹ is chloro.
9. (amended) A compound as claimed in claim 1 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
- B
B
11. (amended) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 1.

Please add Claims 19-55 as follows:

- B
3
19. (new) A compound as claimed in claim 2 wherein X is a direct bond, at least one of R³ and R⁴ is hydrogen, and R² is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.
20. (new) A compound as claimed in claim 3 wherein X is a direct bond, at least one of R³ and R⁴ is hydrogen, and R² is 3-pyridinyl optionally substituted in the 6 position with an optionally substituted alkyl or acyl group are excluded.
21. (new) A compound as claimed in claim 2 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.

- B3*
22. (new) A compound as claimed in claim 3 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
23. (new) A compound as claimed in claim 4 wherein the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
24. (new) A compound as claimed in claim 2 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
25. (new) A compound as claimed in claim 3 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
26. (new) A compound as claimed in claim 4 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
27. (new) A compound as claimed in claim 5 wherein R² is a monocyclic heterocycle selected from pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furanyl, thienyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyranyl, pyridazinyl and triazinyl, wherein said monocyclic heterocycles each independently may optionally be substituted with one, or where possible, two or three substituents each independently selected from Het², R¹¹ and C₁₋₄alkyl optionally substituted with Het² or R¹¹.
- JS 2002*

- B3
28. (new) A compound as claimed in claim 2 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
29. (new) A compound as claimed in claim 3 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
30. (new) A compound as claimed in claim 4 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
31. (new) A compound as claimed in claim 5 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
32. (new) A compound as claimed in claim 6 wherein R³ and R⁴ are both methyl and -X-R² is Het¹.
33. (new) A compound as claimed in claim 2 wherein p is 1 or 2 and each R¹ is chloro.
34. (new) A compound as claimed in claim 3 wherein p is 1 or 2 and each R¹ is chloro.
35. (new) A compound as claimed in claim 4 wherein p is 1 or 2 and each R¹ is chloro.
36. (new) A compound as claimed in claim 5 wherein p is 1 or 2 and each R¹ is chloro.
37. (new) A compound as claimed in claim 6 wherein p is 1 or 2 and each R¹ is chloro.
38. (new) A compound as claimed in claim 7 wherein p is 1 or 2 and each R¹ is chloro.
39. (new) A compound as claimed in claim 8 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
40. (new) A compound as claimed in claim 9 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
- B

- B 3*
cont
41. (new) A compound as claimed in claim 4 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
42. (new) A compound as claimed in claim 5 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
43. (new) A compound as claimed in claim 6 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
44. (new) A compound as claimed in claim 7 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
45. (new) A compound as claimed in claim 8 wherein R³ and R⁴ are both methyl, -X-R² is optionally substituted 2-thiazolyl or 3-oxadiazolyl, the 6-azauracil moiety is in the para position relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents, and p is 2 whereby both R¹ substituents are chloro positioned ortho relative to the carbon atom bearing the -X-R², R³ and R⁴ substituents.
46. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 2.
47. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 3.
48. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 4.

- B 3*
cont
49. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 5.
50. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 6.
51. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 7.
52. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 8.
53. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 9.
54. (new) A composition comprising a pharmaceutically acceptable carrier and, as active ingredient, a therapeutically effective amount of a compound as claimed in claim 10.
55. (new) A compound as claimed in claim 8 wherein the compound of formula (I) contains an ester function.